Massachusetts is currently home to 3200 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Eating to Adjust the Timing System
NCT05800990
Recruiting
The goal of this clinical trial is to test the effects of dietary composition on the rhythms of food intake, appetite regulation, and rhythms of energy expenditure. Participants will: complete 2 field-based dietary interventions be provided with standard meals record daily food intake in a real-time manner complete 2 inpatient stays be provided with standard meals have frequent blood draws provide urine, saliva, and stool samples
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/12/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Dietary Intervention
Register for Updates
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Register for Updates
A SkeleTal Muscle Recovery Intervention with Dietary Protein in Heart Failure
NCT05627440
Recruiting
Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/12/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Heart Failure, Muscle Atrophy
Register for Updates
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT05076396
Recruiting
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
Dose Escalation and Expansion Study of HM16390 in Advanced or Metastatic Solid Tumors
NCT06724016
Recruiting
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into at each dose level. After a comprehensive review of available data from bo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
NCT06006546
Recruiting
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/11/2024
Locations: BIDMC, Boston, Massachusetts
Conditions: Chronic HIV Infection
Register for Updates
Oxytocin Effects on Bone in Children with Autism Spectrum Disorder
NCT05754073
Recruiting
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times daily) for 12 months in the double-blind phase, followed by a 6-month open label phase during which all study subjects will receive intranasal oxytocin (30 IU, 2 times daily). Study visits include screening to determine eligibility, fol... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Autism Spectrum Disorder, Bone Health
Register for Updates
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
NCT05593055
Recruiting
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/11/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypertension, Left Ventricular Hypertrophy
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/11/2024
Locations: Mass General Hospital, Boston, Massachusetts
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates